Merck & Co Inc
6MK
Company Profile
Business description
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. In cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 53% of the company's 2025 sales were generated from US human health (pharmaceuticals and vaccines).
Contact
126 East Lincoln Avenue
RahwayNJ07065
USAT: +1 908 740-4000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
75,000
Stocks News & Analysis
stocks
Chip stock selloff deepens in Asia, extends to Europe and US
The week’s tech stock rout continues despite strong earnings from TSMC and ASML.
stocks
Downgrade for ASX listed fund manager as redemptions pile on
Persistent outflows erode earnings outlook.
stocks
Tesla stock is down nearly 20% this year. Is it a buy ahead of earnings?
Following the rollout of its first autonomous Cybercab, here’s what we expect from Tesla’s earnings report.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,940.40 | 100.00 | 1.13% |
| CAC 40 | 7,956.70 | 22.00 | 0.28% |
| DAX 40 | 25,622.61 | 239.99 | 0.95% |
| Dow JONES (US) | 52,002.41 | 175.28 | -0.34% |
| FTSE 100 | 10,881.90 | 41.55 | 0.38% |
| HKSE | 24,186.83 | 124.11 | 0.52% |
| NASDAQ | 26,140.03 | 572.99 | -2.14% |
| Nikkei 225 | 65,324.29 | 898.34 | 1.39% |
| NZX 50 Index | 13,753.73 | 79.07 | -0.57% |
| S&P 500 | 7,659.44 | 84.62 | -1.09% |
| S&P/ASX 200 | 8,806.70 | 87.00 | 1.00% |
| SSE Composite Index | 3,716.28 | 8.81 | 0.24% |